DUBLIN and MYSTIC, Conn., Oct. 28 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that Dr. Declan Doogan, Chief Medical Officer, is scheduled to present on Amarin’s behalf at the Oppenheimer & Co. Inc. 21st Annual Healthcare Conference on Wednesday, November 3, 2010 at 2:10 pm. This conference will be held at the Waldorf Astoria in New York City. Colin Stewart, Amarin’s President and Chief Executive Officer, will also be at the conference representing Amarin in meetings with investors.
A live audio webcast of the presentation will be available at the following URL:
http://www.veracast.com/webcasts/opco/healthcare2010/06210589.cfm
About Amarin
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia on statin therapy. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
Contacts: | |
Investor Contact Information: | |
John F. Thero | |
Chief Financial Officer | |
In US: +1 (860) 572 4979 | |
Lee M. Stern | |
The Trout Group | |
In U.S. +1 (646) 378-2922 | |
International Media Contact Information: | |
Mark Swallow or David Dible | |
Citigate Dewe Rogerson | |
In UK: +44 (0)207 638 9571 | |
SOURCE Amarin Corporation plc
